Trial Profile
A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Cariprazine (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma America
- 25 Aug 2015 According to an Allergan media release, pooled data from phase II/III studies will be presented at the 28th European College of Neuropsychopharmacology (ECNP) annual congress.
- 19 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 27 Jun 2012 New trial record